Great advances have taken place in the understanding and treatment of pediatric malignant tumors for the past a few decades. However, challenges still exist such as lack of efficient treatments for certain tumors and the side effects and impact of the current treatment options on the growth and development of children with these tumors. Tumor checkpoint blockade immunotherapy has received considerable attention and success in a broad range of tumors including melanoma and non-small cell lung cancer (NSCLC). Dr. He and his collaborators have been working on markers for checkpoint Immunotherapy for pediatric malignant tumors with driver mutations including malignant rhabdoid tumor, NUT midline carcinoma, synovial sarcoma and so on.

Dr. Mai (Mike) He, M.D., Ph.D., is currently an associate professor and section head of Pediatric Pathology in the Department of Pathology & Immunology, Washington University at St. Louis School of Medicine. He is also the Pathologist-in-chief at St. Louis Children’s Hospital. Dr. He received his medical degree from Fudan University Medical Center (formerly Shanghai Medical University), Shanghai, China and his Ph.D. from the Graduate School of Biomedical Science, Rutgers University, Newark, New Jersey. Dr. He completed his AP/CP residency training in Rutgers University New Jersey Medical School, Newark, New Jersey. He had a few additional fellowship training including Molecular and Genetic Pathology (MGP) in the Memorial Sloan Kettering Cancer Center, New York, New York, and is board certified in AP, CP, MGP and Pediatric Pathology. His research interest includes potential targeted and immunotherapy for pediatric cancer.